UA
ENTA icon

Unison Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Unison Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,916
Closed -$721K – 163
2018
Q1 		$721K Hold
8,916
– – 0.54% 67
2017
Q4 		$523K Buy
+8,916
New +$446K 0.38% 73

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Unison Advisors's ENTA Position: Q2 2018 in Review

Unison Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2018, closing a stake of 8,916 shares — an estimated $721K sold.

Unison Advisors first reported a position in ENTA in Q4 2017 and held it in 2 quarters. The position peaked at $721K in Q1 2018. 193 funds tracked by Wall St. Rank hold ENTA as of Q2 2018.

  • Unison Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Unison Advisors sold 8,916 Enanta Pharmaceuticals shares in Q2 2018, an estimated $721K.
  • Unison Advisors first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Unison Advisors's Enanta Pharmaceuticals position peaked at $721K in Q1 2018.
  • 193 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2018.

Based on Unison Advisors's 13F filing for Q2 2018, filed 19 Jul 2018.